Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Blood

Blood

Recruiting

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

The purpose of this study it to examine the safety and efficacy of gene-modified T cell therapy in patients who have previously received the treatment. 

Status
Recruiting
Body Locations and Systems
Blood
Area
Vancouver

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The purpose of this study is to evaluate the safety and efficacy of CC-97540 CAR-T cell treatment for subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.

Status
Recruiting
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Ph+ ALL

The purpose of this study is to compare the efficacy of the drugs ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.

Status
Recruiting
Principal Investigator
Yasser Abou Mourad
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1)

The purpose of this study is to investigate the safety and efficacy of the drug MBG453 as treatment for newly diagnosed Acute Myeloid Leukemia patients when used in combination with other anti-cancer treatments.

Status
Recruiting
Principal Investigator
David Sanford
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

The purpose of this study is to determine whether treatment with Blinatumomab is effective in reducing the risk of acute lymphoblastic leukemia returning in patients with residual cancer cells remaining in the body after stem cell transplant. 

Status
Recruiting
Principal Investigator
David Sanford
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma (ADAM)

This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID). Investigators propose a prospective, cohort study of 24 participants with multiple myeloma, in whom a lenalidomide-dexamethasone (LEN-DEX)-based myeloma treatment regimen is indicated. Eligible participants will initiate thromboprophylaxis with apixaban prior to starting their DEX-containing regimen and continue until the end of cycle 3. Anti-Xa levels, D-Dimer and plasma drug concentration will be measured.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood
Area
Vancouver
Age
19 and above

Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome (SAHaRA Pilot)

The purpose of this study is to determine the feasibility of conducting a large trial examining the effect on clinical outcome of a liberal red blood cell (RBC) transfusion strategy compared to a restrictive strategy (usual care) in patients with aneurysmal subarachnoid hemorrhage (SAH)

Status
Recruiting
Principal Investigator
Donald Griesdale
Body Locations and Systems
Aneurysm
Blood Transfusion and Donation
Area
Vancouver
Age
18 and above

A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib

Imatinib (IM) is first-line treatment for patients with newly diagnosed CML in chronic phase. The drug is associated with high rates of cytogenetic responses with minimal toxicity in approximately 80% of patients. In 20% of patients however, the disease is either initially unresponsive to IM (Imatinib), resistance develops within a few months, or blast crisis occurs early and unexpectedly following an initial response.

Status
Recruiting
Principal Investigator
Donna Forrest
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients (AVERT)

Cancer patients have an increased risk of developing blood clots in the veins compared to non-cancer patients. Cancer patients who develop blood clots can lead to reduced life expectancy, delayed cancer treatment, and decreased quality of life. Prevention is the most effective way to decrease the complications associated with blood clots in the veins.

Status
Recruiting
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood Clots
Area
Vancouver
Age
18 and above

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

This study is a collection of data to evaluate safety and characterize progression of Paroxysmal Nocturnal Hemoglobinuria (PNH).

Status
Recruiting
Principal Investigator
Thomas Nevill
Body Locations and Systems
Blood
Area
Vancouver

Closed for Recruitment

APIxaban Cancer Associated Thrombosis (API-CAT)

The purpose of this study is to determine whether a reduced dose of apixaban is non-inferior to and safer than the full dose of apixaban for the prevention of recurrent venous thromboembolism (VTE) in active cancer patients.

Status
Closed for Recruitment
Principal Investigator
Agnes Lee
Body Locations and Systems
Blood, Heart and Circulation
Blood Clots
Deep Vein Thrombosis
Pulmonary Embolism
Area
Vancouver
Age
18 and above

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON

This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade® or generic equivalent) plus low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple myeloma (MM) regimens. After progressive disease (PD), patients in the Vd Arm may cross over to SVd treatment. Patients who cross over will be referred to as SVdX patients.

Status
Closed for Recruitment
Principal Investigator
Heather J. Sutherland
Body Locations and Systems
Blood
Area
Vancouver
Age
18 years and above

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma

This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with Newly diagnosed multiple myeloma (NDMM).

The study will consist of a dose-finding phase as well as a parallel dose-expansion phase to determine the optimal regimen

Status
Closed for Recruitment
Principal Investigator
Kevin Song
Body Locations and Systems
Blood
Area
Vancouver

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI)

This study will compare the effectiveness of best available surgical treatment with best available endovascular treatment in adults with critical limb ischemia (CLI) who are eligible for both treatment options.

Status
Closed for Recruitment
Principal Investigator
Jerry Chen
Body Locations and Systems
Blood
Arteries
Area
Vancouver
Age
18 and above

Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

This study will independently assess the efficacy and safety of two combination therapies for the treatment of patients with relapsed/refractory multiple myeloma (RR MM): selinexor + dexamethasone + pomalidomide (SdP) and selinexor + dexamethasone + bortezomib (SdB).
 

Status
Closed for Recruitment
Principal Investigator
Heather J. Sutherland
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD)

The purpose of this study is to find out how to increase the potential for achieving an "operational cure" from chronic myeloid leukemia. An "operational cure" is a state in which a person does not require further treatment, although there may be some remaining cancer cells. Patients would normally remain on a TK inhibitor indefinitely within a standard of care setting for chronic myeloid leukemia. Within this clinical trial, patients will discontinue their TK inhibitor prematurely. If any signs of progression are identified, dasatinib will be introduced.

Status
Closed for Recruitment
Principal Investigator
Donna Forrest
Body Locations and Systems
Leukemia
Area
Vancouver
Age
18 and above

A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)

The purpose of the study is to compare once-weekly carfilzomib dosing in combination with dexamethasone to twice-weekly carfilzomib dosing in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma, previously treated with bortezomib and an immunomodulatory agent (IMiD).

Status
Closed for Recruitment
Principal Investigator
Kevin Song
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

An Open-Label Compassionate Use and Long-Term Access Study of Mepolizumab in HES

It is thought that from the efficacy and safety information to date, it is possible that subjects with severe or life-threatening HES, and limited treatment options (unresponsive or intolerant to available HES medication), may benefit from mepolizumab treatment. Such subjects will not be able to access mepolizumab through the aforementioned clinical trials due to the severity of their disease. Waiting for regulatory approval would delay access.

Status
Closed for Recruitment
Body Locations and Systems
Eosinophilic Disorders
Area
Vancouver
Age
12 and above

Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

This is a phase 3, randomized, controlled, open-label, multicenter study of the oral formulation of dexamethasone plus IXAZOMIB compared with treatment chosen by the investigator from a prespecified list of regimens available in clinical practice. Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an immunomodulatory drug (IMiD, thalidomide or lenalidomide) in patients with relapsed or refractory AL amyloidosis.

Status
Closed for Recruitment
Principal Investigator
Kevin Song
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.

Status
Closed for Recruitment
Principal Investigator
Kevin Song
Body Locations and Systems
Blood
Area
Vancouver
Age
18 and above

Pagination

  • Current page 1
  • Page 2
  • Next page
Subscribe to Blood

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy